array(40) {
  [0]=>
  string(4) "1678"
  ["article_id"]=>
  string(4) "1678"
  [1]=>
  string(48) "Flu Shot Much More Effective This Year, CDC Says"
  ["article_title"]=>
  string(48) "Flu Shot Much More Effective This Year, CDC Says"
  [2]=>
  string(154) "THURSDAY, Feb. 14, 2019 -- This year's flu shot is already outperforming the vaccine issued during the tough 2017-2018 influenza season, federal healt"
  ["short_description"]=>
  string(154) "THURSDAY, Feb. 14, 2019 -- This year's flu shot is already outperforming the vaccine issued during the tough 2017-2018 influenza season, federal healt"
  [3]=>
  string(251) "THURSDAY, Feb. 14, 2019 -- This year's flu shot is already outperforming the vaccine issued during the tough 2017-2018 influenza season, federal health officials reported Thursday.&#nlThe 2017-2018 flu shot offered just 25 percent effectiveness..."
  ["description"]=>
  string(251) "THURSDAY, Feb. 14, 2019 -- This year's flu shot is already outperforming the vaccine issued during the tough 2017-2018 influenza season, federal health officials reported Thursday.&#nlThe 2017-2018 flu shot offered just 25 percent effectiveness..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(174) "https://www.drugs.com/news/flu-shot-much-more-effective-year-cdc-says-80465.html?utm_source=ddc&utm_medium=rss&utm_campaign=Flu+Shot+Much+More+Effective+This+Year%2C+CDC+Says"
  ["blog_url"]=>
  string(174) "https://www.drugs.com/news/flu-shot-much-more-effective-year-cdc-says-80465.html?utm_source=ddc&utm_medium=rss&utm_campaign=Flu+Shot+Much+More+Effective+This+Year%2C+CDC+Says"
  [15]=>
  string(19) "2019-02-14 22:02:44"
  ["add_date"]=>
  string(19) "2019-02-14 22:02:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1721"
  ["article_id"]=>
  string(4) "1721"
  [1]=>
  string(62) "Commonwealth antimicrobial stewardship partnerships announced "
  ["article_title"]=>
  string(62) "Commonwealth antimicrobial stewardship partnerships announced "
  [2]=>
  string(150) "A total of 12 pharmacy-led teams from the UK are set to work with their counterparts in 4 African Commonwealth countries in a bid to exchange expertis"
  ["short_description"]=>
  string(150) "A total of 12 pharmacy-led teams from the UK are set to work with their counterparts in 4 African Commonwealth countries in a bid to exchange expertis"
  [3]=>
  string(192) "A total of 12 pharmacy-led teams from the UK are set to work with their counterparts in 4 African Commonwealth countries in a bid to exchange expertise in antimicrobial resistance stewardship."
  ["description"]=>
  string(192) "A total of 12 pharmacy-led teams from the UK are set to work with their counterparts in 4 African Commonwealth countries in a bid to exchange expertise in antimicrobial resistance stewardship."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(140) "https://www.pharmaceutical-journal.com/news-and-analysis/news/commonwealth-antimicrobial-stewardship-partnerships-announced/20206157.article"
  ["blog_url"]=>
  string(140) "https://www.pharmaceutical-journal.com/news-and-analysis/news/commonwealth-antimicrobial-stewardship-partnerships-announced/20206157.article"
  [15]=>
  string(19) "2019-02-14 21:34:00"
  ["add_date"]=>
  string(19) "2019-02-14 21:34:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1722"
  ["article_id"]=>
  string(4) "1722"
  [1]=>
  string(99) "Pharmacy practice has improved 'significantly' since the Gosport tragedy, says new guidance"
  ["article_title"]=>
  string(99) "Pharmacy practice has improved 'significantly' since the Gosport tragedy, says new guidance"
  [2]=>
  string(158) "The pharmacy profession has “moved on significantly” since the events at Gosport War Memorial Hospital, which led to the deaths of hundreds of pat"
  ["short_description"]=>
  string(158) "The pharmacy profession has “moved on significantly” since the events at Gosport War Memorial Hospital, which led to the deaths of hundreds of pat"
  [3]=>
  string(187) "The pharmacy profession has “moved on significantly” since the events at Gosport War Memorial Hospital, which led to the deaths of hundreds of patients, new guidance has said."
  ["description"]=>
  string(187) "The pharmacy profession has “moved on significantly” since the events at Gosport War Memorial Hospital, which led to the deaths of hundreds of patients, new guidance has said."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(167) "https://www.pharmaceutical-journal.com/news-and-analysis/news/pharmacy-practice-has-improved-significantly-since-the-gosport-tragedy-says-new-guidance/20206156.article"
  ["blog_url"]=>
  string(167) "https://www.pharmaceutical-journal.com/news-and-analysis/news/pharmacy-practice-has-improved-significantly-since-the-gosport-tragedy-says-new-guidance/20206156.article"
  [15]=>
  string(19) "2019-02-14 21:14:00"
  ["add_date"]=>
  string(19) "2019-02-14 21:14:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1723"
  ["article_id"]=>
  string(4) "1723"
  [1]=>
  string(88) "NHS review finds 'majority' of pharmacy aseptic services cannot fund maintenance"
  ["article_title"]=>
  string(88) "NHS review finds 'majority' of pharmacy aseptic services cannot fund maintenance"
  [2]=>
  string(150) "Most aseptic pharmacy services in England are unable pay for maintenance and servicing due to a poor understanding of the costs involved, an NHS repor"
  ["short_description"]=>
  string(150) "Most aseptic pharmacy services in England are unable pay for maintenance and servicing due to a poor understanding of the costs involved, an NHS repor"
  [3]=>
  string(161) "Most aseptic pharmacy services in England are unable pay for maintenance and servicing due to a poor understanding of the costs involved, an NHS report has said."
  ["description"]=>
  string(161) "Most aseptic pharmacy services in England are unable pay for maintenance and servicing due to a poor understanding of the costs involved, an NHS report has said."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(166) "https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/nhs-review-finds-majority-of-pharmacy-aseptic-services-cannot-fund-maintenance/20206153.article"
  ["blog_url"]=>
  string(166) "https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/nhs-review-finds-majority-of-pharmacy-aseptic-services-cannot-fund-maintenance/20206153.article"
  [15]=>
  string(19) "2019-02-14 21:09:00"
  ["add_date"]=>
  string(19) "2019-02-14 21:09:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1669"
  ["article_id"]=>
  string(4) "1669"
  [1]=>
  string(54) "Oncology sales drive AstraZeneca’s Q4 Earnings "
  ["article_title"]=>
  string(54) "Oncology sales drive AstraZeneca’s Q4 Earnings "
  [2]=>
  string(150) "AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sal"
  ["short_description"]=>
  string(150) "AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sal"
  [3]=>
  string(192) "AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter."
  ["description"]=>
  string(192) "AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(85) "http://www.pharmatimes.com/news/oncology_sales_drive_astrazenecas_q4_earnings_1278306"
  ["blog_url"]=>
  string(85) "http://www.pharmatimes.com/news/oncology_sales_drive_astrazenecas_q4_earnings_1278306"
  [15]=>
  string(19) "2019-02-14 20:52:59"
  ["add_date"]=>
  string(19) "2019-02-14 20:52:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1670"
  ["article_id"]=>
  string(4) "1670"
  [1]=>
  string(72) "NICE provides first scientific advice on patient preference study design"
  ["article_title"]=>
  string(72) "NICE provides first scientific advice on patient preference study design"
  [2]=>
  string(150) "The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a "
  ["short_description"]=>
  string(150) "The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a "
  [3]=>
  string(175) "The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study."
  ["description"]=>
  string(175) "The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(112) "http://www.pharmatimes.com/news/nice_provides_first_scientific_advice_on_patient_preference_study_design_1278298"
  ["blog_url"]=>
  string(112) "http://www.pharmatimes.com/news/nice_provides_first_scientific_advice_on_patient_preference_study_design_1278298"
  [15]=>
  string(19) "2019-02-14 20:50:05"
  ["add_date"]=>
  string(19) "2019-02-14 20:50:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1671"
  ["article_id"]=>
  string(4) "1671"
  [1]=>
  string(59) "AbCellera collaborates with Novartis for antibody discovery"
  ["article_title"]=>
  string(59) "AbCellera collaborates with Novartis for antibody discovery"
  [2]=>
  string(150) "AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline,"
  ["short_description"]=>
  string(150) "AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline,"
  [3]=>
  string(253) "AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline, using a unique combination of microfluidics, high-throughput imaging, genomics, deep computing and AI."
  ["description"]=>
  string(253) "AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline, using a unique combination of microfluidics, high-throughput imaging, genomics, deep computing and AI."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(99) "http://www.pharmatimes.com/news/abcellera_collaborates_with_novartis_for_antibody_discovery_1278276"
  ["blog_url"]=>
  string(99) "http://www.pharmatimes.com/news/abcellera_collaborates_with_novartis_for_antibody_discovery_1278276"
  [15]=>
  string(19) "2019-02-14 20:46:36"
  ["add_date"]=>
  string(19) "2019-02-14 20:46:36"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1672"
  ["article_id"]=>
  string(4) "1672"
  [1]=>
  string(65) "Johnson & Johnson, Takeda and Evotec join The Dementia Consortium"
  ["article_title"]=>
  string(65) "Johnson & Johnson, Takeda and Evotec join The Dementia Consortium"
  [2]=>
  string(152) "The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industr"
  ["short_description"]=>
  string(152) "The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industr"
  [3]=>
  string(192) "The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industry dementia drug discovery collaboration."
  ["description"]=>
  string(192) "The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industry dementia drug discovery collaboration."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(107) "http://www.pharmatimes.com/news/johnson_and_johnson,_takeda_and_evotec_join_the_dementia_consortium_1278215"
  ["blog_url"]=>
  string(107) "http://www.pharmatimes.com/news/johnson_and_johnson,_takeda_and_evotec_join_the_dementia_consortium_1278215"
  [15]=>
  string(19) "2019-02-14 20:44:52"
  ["add_date"]=>
  string(19) "2019-02-14 20:44:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1673"
  ["article_id"]=>
  string(4) "1673"
  [1]=>
  string(58) "First patient dosed in ADCT-402 Phase I trial for lymphoma"
  ["article_title"]=>
  string(58) "First patient dosed in ADCT-402 Phase I trial for lymphoma"
  [2]=>
  string(150) "ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokineti"
  ["short_description"]=>
  string(150) "ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokineti"
  [3]=>
  string(337) "ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca's Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma."
  ["description"]=>
  string(337) "ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca's Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(98) "http://www.pharmatimes.com/news/first_patient_dosed_in_adct-402_phase_i_trial_for_lymphoma_1278204"
  ["blog_url"]=>
  string(98) "http://www.pharmatimes.com/news/first_patient_dosed_in_adct-402_phase_i_trial_for_lymphoma_1278204"
  [15]=>
  string(19) "2019-02-14 20:26:43"
  ["add_date"]=>
  string(19) "2019-02-14 20:26:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1674"
  ["article_id"]=>
  string(4) "1674"
  [1]=>
  string(55) "Could sound and vision be the future of drug discovery?"
  ["article_title"]=>
  string(55) "Could sound and vision be the future of drug discovery?"
  [2]=>
  string(150) "New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of"
  ["short_description"]=>
  string(150) "New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of"
  [3]=>
  string(186) "New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of various diseases, including cancer."
  ["description"]=>
  string(186) "New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of various diseases, including cancer."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(94) "http://www.pharmatimes.com/news/could_sound_and_vision_be_the_future_of_drug_discovery_1278187"
  ["blog_url"]=>
  string(94) "http://www.pharmatimes.com/news/could_sound_and_vision_be_the_future_of_drug_discovery_1278187"
  [15]=>
  string(19) "2019-02-14 20:20:28"
  ["add_date"]=>
  string(19) "2019-02-14 20:20:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1724"
  ["article_id"]=>
  string(4) "1724"
  [1]=>
  string(81) "Member feedback sought on draft plans for UK-wide Foundation Pharmacist Framework"
  ["article_title"]=>
  string(81) "Member feedback sought on draft plans for UK-wide Foundation Pharmacist Framework"
  [2]=>
  string(133) "The Royal Pharmaceutical Society is seeking members’ help as it plans the design of a UK-wide Foundation Pharmacist Framework."
  ["short_description"]=>
  string(133) "The Royal Pharmaceutical Society is seeking members’ help as it plans the design of a UK-wide Foundation Pharmacist Framework."
  [3]=>
  string(133) "The Royal Pharmaceutical Society is seeking members’ help as it plans the design of a UK-wide Foundation Pharmacist Framework."
  ["description"]=>
  string(133) "The Royal Pharmaceutical Society is seeking members’ help as it plans the design of a UK-wide Foundation Pharmacist Framework."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(146) "https://www.pharmaceutical-journal.com/your-rps/member-feedback-sought-on-draft-plans-for-uk-wide-foundation-pharmacist-framework/20206141.article"
  ["blog_url"]=>
  string(146) "https://www.pharmaceutical-journal.com/your-rps/member-feedback-sought-on-draft-plans-for-uk-wide-foundation-pharmacist-framework/20206141.article"
  [15]=>
  string(19) "2019-02-14 20:20:00"
  ["add_date"]=>
  string(19) "2019-02-14 20:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1692"
  ["article_id"]=>
  string(4) "1692"
  [1]=>
  string(65) "Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women"
  ["article_title"]=>
  string(65) "Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women"
  [2]=>
  string(150) "THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental "
  ["short_description"]=>
  string(150) "THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental "
  [3]=>
  string(251) "THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common..."
  ["description"]=>
  string(251) "THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(198) "https://www.drugs.com/news/rates-osteonecrosis-jaw-low-denosumab-treated-women-80462.html?utm_source=ddc&utm_medium=rss&utm_campaign=Rates+of+Osteonecrosis+of+the+Jaw+Low+for+Denosumab-Treated+Women"
  ["blog_url"]=>
  string(198) "https://www.drugs.com/news/rates-osteonecrosis-jaw-low-denosumab-treated-women-80462.html?utm_source=ddc&utm_medium=rss&utm_campaign=Rates+of+Osteonecrosis+of+the+Jaw+Low+for+Denosumab-Treated+Women"
  [15]=>
  string(19) "2019-02-14 20:00:56"
  ["add_date"]=>
  string(19) "2019-02-14 20:00:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}